Cost of gene therapies ...A 1.77M$ treatment!!!!
Bluebird prices gene therapy Zynteglo at 1.77M$US in Europe, to be paid over 5 years June 17, 2019
After Novartis put a $2.125 million sticker on its spinal muscular atrophy gene therapy Zolgensma, all eyes were on how Bluebird Bio would price its own gene therapy for transfusion-dependent beta-thalassemia (TDT). And now, industry watchers have some answers.
Bluebird will price Zynteglo, formerly known as LentiGlobin, at €1.575 million ($1.77 million) in Europe, the company said during an investor presentation Friday. Just like Novartis did with Zolgensma, Bluebird is offering a five-year, results-driven installment payment plan. After the initial €315,000, patients only pay the same amount each year thereafter if they continue to respond to the therapy.
As for the U.S., where Bluebird expects to win a Zynteglo go-ahead in 2020, the company said it plans to price the drug within a “reasonably close” range, Reuters reported.
.